A phase II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Trial Profile

A phase II trial of Octreotate-Lu-177-DOTA-Tyr-3 in patients with various inoperable, somatostatin receptor positive NETs including bronchial carcinoid tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
  • Indications Carcinoid tumour; Neuroendocrine tumours; Paraganglioma; Phaeochromocytoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Feb 2018 According to an Advanced Accelerator Applications media release, Advanced Accelerator Applications is acquired by Novartis
    • 26 Jan 2018 According to a Food and drug administration media release, based on results from this and NETTER-1 trials the U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointestinal tract called gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    • 29 Sep 2017 According to an Advanced Accelerator Applications media release, the European Commission (EC) has approved the marketing authorization of lutetium (177Lu) oxodotreotide (Lutathera) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adults. The approval is based on results from this and NETTER-1 trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top